Nathalie Cartier-Lacave

Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ.

Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France.

Part of Novartis AG, Novartis Seeds AG is a company that manufactures agro-chemical products. The company is based in Novartis, Switzerland.

Axiad IDS, Inc. provides passwordless orchestration for enterprise and public sector organizations to secure people, machines, and interactions. The company is based in Santa Clara, CA. The company's flagship product, Axaid Cloud, is a comprehensive, secure, and integrated authentication platform that allows customers to move to a passwordless future without the friction and risk of fragmented solutions. Axaid offers unified credential management for all employees' authentication needs, including certificates, mobile MFA, TPM, hardware tokens, smart cards, and biometrics. The company was founded in 2010 by Yves Audebert and Bassam Al-Khalidi, and they have been the CEOs since 2010.

GlobalPlatform, Inc. is a technical standards organization that provides standardized technologies and certifications to empower technology and service providers to develop, certify, deploy, and manage digital services and devices in line with their business, security, regulatory and data protection needs. The non-profit company is based in Redwood City, CA. Its platform technologies are used in billions of smart cards, smartphones, wearables and other connected IoT devices. The company achieves end-to-end security, privacy, simplicity, and convenience to users by enabling the efficient launch and management of innovative, secure-by-design digital services and devices. The company's standardized technologies and certifications are developed through effective industry-driven collaboration, led by multiple diverse member companies working in partnership with industry and regulatory bodies and other interested parties from around the world.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.